Core Insights - Enanta Pharmaceuticals, Inc. announced positive topline data from a Phase 2b study evaluating zelicapavir for treating acute RSV infection in high-risk outpatient adults [1] Group 1: Study Details - The study, named RSVHR, is a randomized, double-blind, placebo-controlled trial [1] - The focus is on outpatient adults with acute RSV infection who are at high risk of complications, including the elderly [1]